's  Instablog
Send Message is a leading provider of real-time SEC filings alerts and in-depth analysis with over 600,000 registered users.

My company:
SEC Filings
My blog:
  • Pharmaceutical Stocks Outperform The S&P 500 By 20% YTD 0 comments
    Nov 4, 2013 1:19 PM | about stocks: GALT

    The SPDR S&P 500's (NYSE: SPY) 23% jump so far this year is impressive, but the pharmaceutical sector has proven to be an even better bet. Since January, the SPDR S&P Pharmaceuticals ETF (NYSE: XPH) has jumped 43% higher, outperforming the S&P 500 by 20% or nearly double. While a lot of uncertainties remain within the healthcare system, the innovation coming out of the pharmaceutical sector continues to drive financial results and equity valuations higher.

    Will Pharma Stocks Continue Higher?

    New drugs and research advances have led the pharmaceutical industry to outperform many other segments of the S&P 500, but the Affordable Care Act ("ACA") could prove to be its greatest catalyst moving forward. According to GlobalData of London, the new healthcare law could bring in between $10 billion and $35 billion of additional profit over the next decade, helping the industry expand 33% to $476 billion in size by 2020.

    Despite expiring patents on blockbuster drugs and the cost of implementing the ACA, pharmaceutical companies are well positioned to benefit from the dramatic expansion of those covered by health insurance. GlobalData projects that Medicaid alone is projected to expand by about 19.5 million people, while 32 million formerly uninsured citizens become potential new customers - and customers that are less likely to use generics.

    Of course, the industry's success may hinge on the successful implementation of the new healthcare law. Increasing patient populations will help expand its revenues, but without them, expiring blockbuster patents and a lack of innovation - at least compared to the faster-growing biotech sector - could provide difficult hurdles to overcome. But at least for now, it seems likely that the ACA will proceed as planned over the coming couple years.

    Investing in Pharma Equities with ETFs

    The easiest way for investors to capitalize on the outperformance of the pharmaceutical industry is by leveraging its many exchange-traded funds ("ETFs"). According to data from ETFdb in Figure 1 below, all four of the largest pharmaceutical ETFs outperformed the S&P 500 so far this year by margins of between 4% and 20%, depending on the ETF. In addition to their strong performance, the funds offer instant diversified exposure to the sector.



    Total Assets ('000)

    YTD Performance


    PowerShares Dynamic Pharmaceuticals Portfolio




    SPDR S&P Pharmaceuticals ETF




    iShares Dow Jones US Pharmaceuticals Index Fund




    Market Vectors Pharmaceutical ETF



    Figure 1 - Pharmaceutical ETF Performance - Source:

    Of course, it's important for investors to realize that most of these pharmaceutical ETFs primarily hold "big pharma" components. For example, the top holdings in the SPDR S&P Pharmaceuticals ETF include larger companies like Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie Inv. (NYSE: ABBV) - the spin-off from Abbott Laboratories (NYSE: ABT). Greater growth and diversification could be seen in smaller players within this industry.

    Big Pharma Versus Smaller Equities

    Big pharmaceutical companies, like Pfizer Inc. (NYSE: PFE) or Merck & Co. (NYSE: MRK), may account for the majority of the major pharmaceutical ETFs. But many investors are concerned that these large companies may be overvalued after their rally. For example, Pfizer trades with a price-earnings ratio of 20.2x, which is higher than the industry average of 16.8x, the S&P 500 average of 17x, and even its own 5-year average of 17.2x, which is perhaps the most relevant.

    Investors may therefore want to take a look at some smaller equities in the space, including those that are valued on their future potential rather than current earnings. For example, Galectin Therapeutics Inc. (NASDAQ: GALT) has surged more than 400% so far this year, based on study results showing that tumor cells secrete galectin-3 (its target), which binds to, and blocks the action of, tumor-infiltrating T-lymphocytes, the body's major immune defense.

    While GM-CT-01 is in Phase I/II proof-of-concept clinical trials to treat melanoma, GR-MD-02 has the potential to treat non-alcoholic steatohepatitis (NASH, part of the fatty liver disease/fibrosis/cirrhosis progression) patients and even reverse scarring in the liver. The reduction in scarring for the liver - and other organs in preclinical trials - could revolutionize fibrosis research and produce a blockbuster drug, if approved. Currently, GR-MD-02 is in Phase I clinical trials under a Fast Track designation from the FDA with the first patient dosed in July.

    A slightly larger small-cap in the space is The Medicines Company (NASDAQ: MDCO), which has four drugs pending approval by the FDA in 2014. The company also markets four drugs, including Argatroban, Recothrem, Recothrem and the biggest seller, Angiomax. Angiomax has generated more than $540 million in revenues last year, providing an element of stability, while several partnerships with industry leaders could further enhance its long-term growth.

    The Medicines Company also trades with a price-earnings to growth ratio of just 0.7x, suggesting that it may be undervalued given its growth rates, despite a 35x trailing price-earnings ratio and 3.1 price-sales ratio that may indicate otherwise on the surface. These trends also appear set to continue with favorable inventory growth that regularly surpasses its revenue growth, which tends to suggest that future revenues will continue to surpass past revenues.

    Final Thoughts

    The pharmaceutical industry has been among the stock market's top performers this year, nearly doubling the performance of the S&P 500 index. While most investors gain exposure via ETFs that invest in big pharma, those concerned about valuations may want to instead begin to diversify their portfolio into small-cap pharmaceutical companies, keeping in mind that they involve greater operational, financing, and liquidity risks.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Additional disclosure: TDM Financial is a marketing and consulting firm that specializes in creating ongoing communications strategies for public and private companies. For full disclosure please visit:

    Stocks: GALT
Back To's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.